Adherence (Part 1) - The challenge of non-adherence in hyperphosphatemia
|
|
- Margery Walton
- 5 years ago
- Views:
Transcription
1
2 Adherence (Part 1) - The challenge of non-adherence in hyperphosphatemia Phosphate binders have been shown to be effective in regulating phosphorus levels 1,2 and yet according to a recent large observational study, 3 50% of patients have serum phosphorous concentrations outside the target range. Clinical studies have demonstrated the efficacy of phosphate binders in controlling serum phosphorus and observational studies confirm their widespread use, 1 so to what extent is the difficult of controlling phosphorus levels caused by non-adherence to binder regimens? 4 Phosphate binders have shown to be effective at controlling phosphorus levels Phosphate binders are widely used in dialysis patients to control phosphate levels and observational studies have shown their use to be associated with improved survival outcomes. In a study of 6,797 dialysis patients Cannata-Andia et al. found that patients prescribed phosphate binders had 29% lower all-cause mortality risk and a 22% lower cardiovascular mortality risk. 1 Treatment with phosphate binders was independently associated with decreased mortality in an observational study of 10,044 incident dialysis patients. 2 Despite the widespread use of binders, phosphorus levels in general are poorly controlled, with 50% of patients in a recent study 3 found to have poorly controlled phosphorus levels at baseline. One possible reason for this is the underestimation of the amount of highly absorbable, hidden phosphorus in Western diets, which has been shown to be particularly high in processed foods. 5 Alongside this, there is also a growing body of evidence highlighting that many dialysis patients are not adhering to their binder medication. 1
3 Evidence suggests patient adherence to phosphate binders is poor Non-adherence is a problem in many chronic diseases, but can be especially challenging for dialysis patients due to a complex treatment regimen involving both dietary restrictions and multiple medications. Numerous studies have shown that the prevalence of patient non-adherence to phosphate binder treatments is high: A survey in 2010 found 76% of nephrologists and 63% of dialysis staff thought non-adherence was the main reason for poor control of phosphorus levels in patients. 6 In a cross-sectional study, 502 haemodialysis patients responded to a questionnaire with approximately 70% stating they were non-adherent to phosphate binders. 7 A recent study of Spanish dialysis patients found that 60% were non-adherent to their phosphate binder treatment regimens. 8 In another study by the same author, results found that in 165 dialysis patients, 40% were non-adherent to their treatments and 21% admitted nonadherence to phosphate binders. 9 A systemic review of 34 studies found non-adherence rates averaged at 51% and ranged from 22% to 74%. The result of this review highlighted the variability in measures of adherence. 10 These data suggest that non-adherence is an important issue in phosphate binder therapy and it is a logical step to suggest that improving these adherence rates could lead to better treatment outcomes for dialysis patients. This is the first in a series of articles discussing adherence, outcomes & pill burden in hyperphosphatemia. In our next article we will look at associations between adherence and improved outcomes. 2
4 References 1. Cannata-Andía JB, Fernández-Martín JL, Locatelli F, et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84(5): doi: /ki Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol JASN. 2009;20(2): doi: /asn (last seen on June 6 th, 2014) 4. Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153. doi: / Carrigan A, Klinger A, Choquette SS, et al. Contribution of Food Additives to Sodium and Phosphorus Content of Diets Rich in Processed Foods. J Ren Nutr. 2014;24(1):13-19.e1. doi: /j.jrn Toussaint ND, Pedagogos E, Beavis J, Becker GJ, Polkinghorne KR, Kerr PG. Improving CKD- MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant. 2010:gfq602. doi: /ndt/gfq Martins MTS, Silva LF, Kraychete A, et al. Potentially modifiable factors associated with nonadherence to phosphate binder use in patients on hemodialysis. BMC Nephrol. 2013;14(1):208. doi: / Dolores Arenas M, Pérez-García R, Bennouna M, et al. Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study. Nefrol Publ Of Soc Esp Nefrol. 2013;33(2): doi: /nefrologia.pre2012.oct Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol. 2010;23(5): Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9(1):2. doi: /
5 Adherence (Part 2) - Is adherence to phosphate binder therapy associated with improved outcomes? Research and clinical experience suggests that adherence to phosphate binders is low, but will improving adherence lead to better outcomes? A meta-analysis of 21 studies, in diseases such as HIV, myocardial infarction and type II diabetes, found that good adherence to drug therapy is associated with positive health outcomes. 1 But does similar evidence exist for adherence to phosphate binder treatment? Non-adherence is associated with poor control of phosphorus levels A number of studies have examined the association between adherence to phosphate binders and serum phosphorus levels. From the recent literature: Arenas et al. found that haemodialysis patients who were non-adherent to phosphate binders were significantly more likely to have high phosphorus than adherent patients. Non-adherence to phosphate binders was greater than for hypotensive agents, suggesting dialysis patients may have increased difficulty following binder regimens. 2 A study of 76 peritoneal dialysis patients found adherence to phosphate binders was greatest in patients with low phosphorus levels. Multivariate analysis showed adherence was the only significant contributor to high serum phosphorus levels. 3 In an analysis of 8,616 patients, lower adherence was associated with higher mean phosphorus levels and a lower percentage of patients with serum phosphorus 5.5 mg/dl. 4 At ASN Kidney Week 2012, Tentori et al. presented an analysis of the DOPPS 5 registry showing non-adherence to phosphate binders was associated with high phosphorus and PTH levels. Studies such as these suggest that improved adherence may lead to a greater control of serum phosphorus, and a reduced risk of hyperphosphatemia. Given the well-documented links between high serum phosphorus levels and increased mortality in dialysis patients, 6 it seems likely that improving adherence to phosphate binders will have a positive effect on hard outcomes, similar to that seen from improved adherence in other diseases. 4
6 Improving adherence may also deliver financial benefits Poor adherence could also be leading to over-prescription of phosphate binders and a higher pill burden, as physicians escalate their attempts to control high phosphorus levels. 7 This over-prescription also has the potential to increase medication cost. A recent review focusing on the cost of adherence in multiple disease areas concluded that non-adherence is a significant contributor to avoidable healthcare costs in the US, and improving adherence could save billions of dollars per year. 8 But how to improve adherence? Evidence suggests that improved adherence to phosphate binders could improve outcomes and potentially lower medication costs. But how can clinicians improve adherence? The starting point for this analysis needs to be an understanding of why patients are not adhering to phosphate binders, and this will be the focus of our next few articles on COMPACT Renal. 5
7 References 1. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. doi: /bmj Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol. 2010;23(5): Hung K-Y, Liao S-C, Chen T-H, Chao M-C, Chen J-B. Adherence to phosphate binder therapy is the primary determinant of hyperphosphatemia incidence in patients receiving peritoneal dialysis. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2013;17(1): doi: /j x. 4. Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc doi: /ndt/gft (last seen on June 6 th, 2014) 6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol JASN. 2004;15(8): doi: /01.asn a2. 7. Chiu Y-W, Teitelbaum I, Misra M, Leon EM de, Adzize T, Mehrotra R. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clin J Am Soc Nephrol doi: /cjn Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7: doi: /rmhp.s
8 Adherence (Part 3) - Why do patients not adhere to therapies? A high percentage of dialysis patients do not adhere to their phosphate binder medication, which leads to poor control of serum phosphorus levels. What factors contribute to this non-adherence? Adherence is a multi-factorial problem Studies investigating the causes of non-adherence across multiple diseases have found it to be a multifactorial problem. Not only do adherence rates vary between patients, they also vary for the same individual over time and across treatments. 1 In fact, most patients are non-adherent at some point in time. 1 Some of the reasons found for non-adherence to therapies are: Psychological factors Psychosocial factors include patients beliefs about their treatment, the amount of social support they receive and even certain personality traits. A systematic review of 34 studies on adherence to phosphate binders found that psychosocial factors were the most promising predictors of nonadherence. 2 However, pill burden as a predictor of adherence was not assessed in this review. 2 Need for lifestyle modification One study found adherence to binders to be lowest in patients who had to change their lifestyle in order to adhere. 3 Cost-to-patient of medication In a review of 160 articles, across multiple diseases, on the relationship between treatment costs-to-patient and adherence, increases in patient cost sharing were associated with declines in medication adherence, which in turn were associated with worse health outcomes. 4 Demographic variables Demographic factors such as age, gender, education and ethnicity have all been suggested as factors that can influence adherence. However, in a systematic review of studies related to phosphate binders, only age was associated with adherence. 2 7
9 Some factors are particularly relevant to phosphate binder treatment Two potential causes of non-adherence have particular relevance for patients prescribed phosphate binders. High pill burden, combined with regimen complexity Dialysis patients have a high pill burden. One study estimated the average pill burden to be nineteen pills per day, of which phosphate binders contributed about half. 5 Phosphate binder regimens are also relatively complex, involving multiple doses per day administered with meals. 5 A recent study has shown that a lower pill burden was associated with greater adherence. 6 8
10 Medication preference and poor tolerability of binders One study found that non-adherence to phosphate binders was associated with medication preferences. Perhaps unsurprisingly, patients on a phosphate binder that they did not like showed lower adherence than patients who did like their treatment. 7 This is a particularly significant factor in haemodialysis patients as many binders have relatively poor tolerability over time, with patient-reported side effects a common reason for binder discontinuation. 8 Both tolerability and pill burden appear to be practical, modifiable targets for improving adherence in hyperphosphatemic patients. We will examine these issues in greater detail in our next articles. References 1. Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, Adherence and Compliance in Medicine Taking: Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). NCCSDO; Available at: data/assets/pdf_file/0009/64494/fr pdf. 2. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9(1):2. doi: / Arenas MD, Malek T, Gil MT, Moledous A, Alvarez-Ude F, Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? J Nephrol. 2010;23(5): Eaddy MT, Cook CL, O Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T Peer-Rev J Formul Manag. 2012;37(1): Chiu Y-W, Teitelbaum I, Misra M, Leon EM de, Adzize T, Mehrotra R. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clin J Am Soc Nephrol doi: /cjn Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc doi: /ndt/gft Arenas MD, Rebollo P, Malek T, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol. 2010;23(6): Wang S, Anum EA, Ramakrishnan K, Alfieri T, Braunhofer P, Newsome B. Reasons for phosphate binder discontinuation vary by binder type. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2014;24(2): doi: /j.jrn
11 Adherence (Part 4) - Why do patients not adhere to phosphate binders: poor tolerability? Poor drug tolerability may be a reason why more than half of dialysis patients, on average, do not adhere to phosphate binder medication. 1 With the range of available phosphate binders likely to expand in the next year, 2 physicians may be able to improve adherence by selecting more appropriate binders for their patients. A recent paper by Wang et al. identified poor toleration of side-effects as a major reason for discontinuation of phosphate binder treatment. 1 In this study, 30,933 patient records were retrospectively analysed to assess the reasons behind phosphate binder discontinuation. 50% of records did not contain a reason for discontinuation and 27% of discontinuations were due to lab results. In this latter category, hypophosphatemia (42%) and hypercalcemia (24%) were the largest attributed causes of discontinuation due to lab results. 11% of discontinuations, the next largest cohort, were due to patient not tolerating and further analysis of this group presented some interesting findings. Nearly 48% of these patients discontinued therapy due to gastrointestinal upset and there was noticeable variation in the reasons for discontinuation between specific binders. Poor tolerability of binders may be a modifiable cause of non-adherence While discontinuing therapy, and noting this in the patient record, does not equate to non-adherence, there is likely to be a high degree of overlap between the two factors. Results from a cross-sectional study of approximately 500 patients support this relationship between adherence and tolerability. Almost 15% of patients who were classified as non-adherent in this study (and approximately 6% of those classified as adherent) reported that they always or almost always stopped taking phosphate binders on their own initiative after feeling worse. 3 This intentional non-adherence to therapy may be modifiable with closer consideration of the side effects of particular binders. The Wang et al. study highlights some factors that clinicians may wish to consider when selecting a phosphate binder for an individual patient. Such individualization of treatment could be rewarded with increased medication adherence and, potentially, improved outcomes. This process is also likely to be supported in future by a wider range of available therapy options, with different tolerability profiles. 2 10
12 References 1. Wang S, Anum EA, Ramakrishnan K, Alfieri T, Braunhofer P, Newsome B. Reasons for phosphate binder discontinuation vary by binder type. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2014;24(2): doi: /j.jrn Ketteler M, Biggar PH. Use of phosphate binders in chronic kidney disease: Curr Opin Nephrol Hypertens. 2013;22(4): doi: /mnh.0b013e d4. 3. Martins MTS, Silva LF, Kraychete A, et al. Potentially modifiable factors associated with nonadherence to phosphate binder use in patients on hemodialysis. BMC Nephrol. 2013;14(1):208. doi: /
13 Adherence (Part 5) - Why do patients not adhere to phosphate binders: high pill burden? Pill burden is recognized as a factor that can affect adherence in a number of diseases, such as HIV. 1 For dialysis patients, the daily pill intake is very high, with a large proportion of this burden comprised of phosphate binders. 2 Given that nonadherence to phosphate binders is common, is there evidence that shows a direct association between pill burden and adherence in dialysis patients? Studies show that high pill burden affects adherence in phosphate binder treatment In a cross-sectional study of 233 US dialysis patients, Chiu et al. found that 62% of patients were non-adherent and adherence decreased significantly with pill count. 2 The study results also suggested that low adherence could lead to over-prescription of phosphate binders and so to a greater pill burden. This clinical approach potentially creates a self-fulfilling, repeating cycle of low adherence, poor phosphorus control and dose escalation. 12
14 Importantly, overall pill burden was associated with a low physical component summary score of the SF-36 QoL (Quality of Life) assessment. Increasing the number of pills prescribed did not improve control of serum phosphorus levels and further reduced the patient s quality of life assessment. 2 Recently, Wang et al also found that increasing pill burden was associated with nonadherence, and non-adherence in turn was associated with poorly controlled serum phosphorus levels. 3 Using data from a pharmacy management program, the investigators tracked dialysis patients on phosphate binder monotherapy over time. 8,616 haemodialysis patient records were analysed, and their medication possession ratio (MPR) and pill burdens were calculated. The Medication Possession Ratio is the proportion of days the patient has sufficient medication available to have taken the medication as prescribed. It is commonly used as an indirect measure of adherence, with a low MPR implying low adherence. An MPR of 100% would suggest perfect adherence. The Wang et al. study found that: Weighted MPR levels were low overall, ranging from 51% to 42% in different cohorts, MPR increased as pill burden decreased, with adherence strongest (51%) in the group with the lowest pill burden (0-3 pills per day), and Higher MPR was associated with worse control of phosphorus to target ranges. These results suggest that a lower pill burden results in greater adherence and lower phosphorus levels. The MPR levels of 40% to 50% align well with other real-world, medication adherence data, lending eight to this observational study. While high pill burden is only one of several factors that may be contributing to poor adherence in dialysis patients, reducing this pill burden is a practical and achievable goal. Switching the type of binders used in patients to those which require less pills per day may deliver some of the improvements in adherence and outcomes that clinicians are seeking. 13
15 References 1. Nachega JB, Parienti J-J, Uthman OA, et al. Lower Pill Burden and Once-daily Dosing Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis Off Publ Infect Dis Soc Am doi: /cid/ciu Chiu Y-W, Teitelbaum I, Misra M, Leon EM de, Adzize T, Mehrotra R. Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clin J Am Soc Nephrol doi: /cjn Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc doi: /ndt/gft
16 Adherence (Part 6) - Improving adherence through treatment optimization and simplifying regimens Patients can find it challenging to adhere to complicated treatment regimens. For example, elderly patients who have cognitive or memory impairments may find therapy compliance difficult, 1 and younger patients may struggle to adapt their lifestyle to treatment demands. 2 This article will look at different ways in which treatment strategies can be adjusted in order to reduce regimen complexity and potentially improve adherence. Simplifying dosing demands Kripalani et al. analysed 37 randomized controlled trials, across multiple chronic diseases, which described interventions intended to enhance patient adherence to self-administered medications. The review found that the most effective approaches were behavioural interventions that simplified dosing demands. 3 A systematic review of 76 studies also showed that simpler, less frequent dosing regimens are associated with better adherence in a variety of diseases. 4 Similarly, a Cochrane Review of hypertensive patients also found that reducing the number of daily doses increases adherence. 5 However, reducing the frequency of phosphate binder dosing is particularly challenging as pills must be taken at every meal. Despite this it may be possible to: 1. Reduce the number of phosphate binders that need to be taken at each meal, and 2. Rationalize the dosing regimens of binder and non-binder medications, for example by equating a morning dose to with breakfast. Reminder systems A randomized clinical trial found that a personalized cell phone reminder system was capable of improving adherence to antiretroviral therapy in 23 HIV patients. 6 Similarly a Cochrane review of interventions to improved adherence to lipid lowing drugs found that the most effective interventions were based on reminder systems. 7 Dose packaging strategies A systematic review of the adherence benefits of packaging pills with a calendar and/or pill organisers found that six out of ten trials reported higher adherence. However in only one study did this relate to clinically significant improvement. 8 15
17 Individualized treatment plans Healthcare professionals can also draft specific treatment plans for patients. A Cochrane review by Gray et al. showed that individualized care planning improved adherence in glaucoma patients. 9 Personal treatment plans may also have greater importance in patients with multiple comorbidities, where each condition has its own treatment regimen. Pharmacists have an increasing role to play in developing these plans, through programs such as Medicare s Medication Therapy Management. 10 References 1. Andrade ASA, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;41(6): doi: / Horne R, Weinman J, Barber N, Elliott R, Morgan M. Concordance, Adherence and Compliance in Medicine Taking: Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). NCCSDO; Available at: data/assets/pdf_file/0009/64494/fr pdf. 3. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6): doi: /archinte Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8): Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004;(2):CD doi: / cd Hardy H, Kumar V, Doros G, et al. Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy. AIDS Patient Care STDs. 2011;25(3): doi: /apc Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;(3):CD doi: / cd pub3. 8. Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR. Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review. Clin Ther. 2011;33(1): doi: /j.clinthera Gray TA, Orton LC, Henson D, Harper R, Waterman H. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev. 2009;(2):CD doi: / cd pub (last seen on May 22 nd, 2014) 16
18 Adherence (Part 7) - Improving adherence through increased patient education Educational interventions have been found to increase adherence in multiple diseases, although reported effects have been inconsistent and studies have largely been short-term. 1 In this article we review whether patient education can similarly improve adherence to phosphate binder medication. Educational programmes can improve patient adherence Several studies have shown that educational sessions or programs regarding phosphate management have led to improved adherence and/or treatment outcomes. In a randomized controlled trial of 56 dialysis patients, those who attended one-to-one teaching sessions, aimed at improving patients knowledge of phosphate management, showed a significant reduction in serum phosphorus concentrations compared to control. 2 Gardulf et al. studied 43 CKD patients (most on dialysis) attending a 2-month educational program regarding calcium and phosphate balance, food intake and phosphate binders. The group exhibited significantly reduced plasma phosphate for up to 12 months afterwards. 3 A nurse-led educational and counselling session provided to 41 patients on phosphate binders resulted in an increase in adherence from 83% to 94% after 13 weeks. The control group s adherence decreased from 86% to 76%. 4 Another nurse-led education program over 12 weeks saw a significant improvement in the proportion of patients who took their phosphate binder correctly, increasing from 44 to 72%, although this did not lead to a statistically significant change in clinical markers. 5 A Phosphate Education Program in children with CKD used phosphorus units to allow patients to quickly estimate phosphorus content in foods and self-adjust binder dosing. Within 6 weeks after training, the percentage of children with serum phosphate outside of the target range dropped from 63% to 31%. 6 While these studies suggest benefits from patient education regarding phosphate management, there is a clear need for a randomized controlled trial evaluating educational interventions over an extended period. This is in line with a 2008 Cochrane Review of interventions for enhancing adherence across multiple conditions, which concluded that high priority should be given to fundamental and applied research concerning innovations to assist patients to follow medication prescriptions for long-term medical disorders. 1 17
19 Patients would like more information about phosphate management This need for further research is especially apparent when we consider patients current levels of understanding about their treatment goals. In one study, 84% of surveyed patients had heard of phosphate, but 42% were unsure of high phosphate foods and 46% were unaware of consequences of elevated phosphate. 7 This Australian study also revealed an interesting symmetry between patients and nephrologists: 74% of patients wanted to know more about CKD-MBD (40% via written material), 84% of nephrologists believed that their patients wanted to know more about CKD-MBD, but Only 28% provided written patient materials on CKD-MBD. Adherence to phosphate binders: a quick summary We have reviewed the topic of adherence over the past few weeks on COMPACT Renal. In summary: Adherence to phosphate binder therapies in dialysis patients is poor, with approximately half of patients non-adherent Non-adherence to phosphate binders is associated with poor control of serum phosphorus which is associated in turn with worse disease outcomes While non-adherence is a complex, multifactorial problem, there are a number of potentially modifiable factors that clinicians could address in order to improve compliance Reducing pill burden and optimizing therapies to improve tolerability are two possible approaches that may bring specific benefits in dialysis patients Simplifying dosing regimens and improving patient education may also lead to improved medication adherence 18
20 References 1. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; Ashurst I de B, Dobbie H. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. J Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2003;13(4): Gardulf A, Pålsson M, Nicolay U, Swedish Renal Nurse Group. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life. Clin Nephrol. 2011;75(4): Van Camp YP, Huybrechts SA, Van Rompaey B, Elseviers MM. Nurse-led education and counselling to enhance adherence to phosphate binders. J Clin Nurs. 2012;21(9-10): doi: /j x. 5. Sandlin K, Bennett PN, Ockerby C, Corradini A-M. The impact of nurse-led education on haemodialysis patients phosphate binder medication adherence. J Ren Care. 2013;39(1): doi: /j x. 6. Ahlenstiel T, Pape L, Ehrich JHH, Kuhlmann MK. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2010;25(10): doi: /ndt/gfq Toussaint ND, Pedagogos E, Beavis J, Becker GJ, Polkinghorne KR, Kerr PG. Improving CKD- MBD management in haemodialysis patients: barrier analysis for implementing better practice. Nephrol Dial Transplant. 2010:gfq602. doi: /ndt/gfq
21 Adherence (Part 8) CompAct expert view: Dr Stuart Sprague on the importance of low pill burden in the treatment of hyperphosphatemia In a new video interview for COMPACT, Dr Stuart Sprague from the University of Chicago discusses the optimal approach to phosphate management in dialysis patients. Dr Sprague highlights that effective, tolerable, and low pill burden phosphate binders are key to patient adherence in this highly medicated patient population. Transcript Hello, I'm Dr Stuart Sprague. I'm currently at North Shore University Health Systems and on the faculty at University of Chicago Pritzker School of Medicine. I'd like to take a few minutes right now and talk to you about the optimal, integrated approach towards phosphate management in dialysis patients. I'm sure we all realize that regulating serum phosphate is very important for a patient's optimal health and outcome, and it's become a very difficult aspect for many patients to do. Generally, the integrated approach toward phosphate management includes: Dietary counselling and the restriction of foods that are high in inorganic phosphates, without excessively restricting protein. The use of adequate dialysis. The appropriate use of medication, such as vitamin D compounds so we don't enhance phosphate absorption. Appropriate management of parathyroid hormone and adequate dialysis. However, the mainstay and probably the most important feature of taking care of these patients is that of using phosphate binders. When we want to approach phosphate binders, we want to make sure that they have low GI side effects, that patients do tolerate them, and that they're able to take them with their meals, and probably one of the biggest aspects is that of patient compliance and adherence, [which is related to] the number of phosphate binders the patient has to take. 20
22 If we consider that many dialysis patients take well over 20 pills a day, and frequently half of those pills are phosphate binders, we then can appreciate how difficult it may be for patients to become compliant or adherent with their phosphate binders, as it becomes difficult to take 2, 3, or 4 pills with each meal, especially these pills that affect the taste of the meal in a negative way. So therefore, patient adherence and compliance is something that we have to accomplish by using phosphate binders that are effective, tolerable, and require a low pill burden. Having patients having a low pill burden will then enhance their ability to take these binders as prescribed. 21
The Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationTHE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION
THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationAdvanced Chronic Kidney Disease and Secondary Hyperparathyroidism (HPT): Multidisciplinary Management
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/advanced-chronic-kidney-disease-andsecondary-hyperparathyroidism-multi-disciplinary-management/9570/
More informationSimon Leung 1, Brendan McCormick 2,3, Jessica Wagner 3, Mohan Biyani 2, Susan Lavoie 2, Rameez Imtiaz 4 and Deborah Zimmerman 2,3,5*
Leung et al. BMC Nephrology (2015) 16:205 DOI 10.1186/s12882-015-0205-3 RESEARCH ARTICLE Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal
More informationVelphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationLanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding
Renal Failure, 34(3): 263 270, (2012) Copyright Informa Healthcare USA, Inc. ISSN 0886-022X print/1525-6049 online DOI: 10.3109/0886022X.2011.649657 Lanthanum Carbonate Reduces Urine Phosphorus Excretion:
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Guideline (2010) Chronic Kidney Disease CKD: Executive Summary of Recommendations (2010) Executive Summary of Recommendations Below are the major recommendations
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationCowen Healthcare Conference March 12, 2018
Cowen Healthcare Conference March 12, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationLocation of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON
Story #1 CSHP 2015 objective Objective 2.1 - In 70% of ambulatory and specialized care clinics providing clinic care, pharmacists will manage medication therapy for clinic patients with complex and high-risk
More informationAssessing Medication Adherence
Assessing Medication Adherence Dr. Lauren Hanna and Dr. Delbert Robinson Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationHome Dialyzors United
Home (HDU) is pleased to offer The University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) comments concerning its upcoming report to CMS which investigates avenues for acquiring the evidence,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPotentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis
Martins et al. BMC Nephrology 2013, 14:208 RESEARCH ARTICLE Open Access Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis Maria Tereza Silveira
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationHyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence
Covic and Rastogi BMC Nephrology 2013, 14:153 REVIEW Open Access Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence Adrian Covic 1,2* and
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More informationChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationImproving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies
Improving Medication Adherence through Collaboration between Colleges of Pharmacy and Community Pharmacies Megan Willson, PharmD, BCPS; Catrina Schwartz, PharmD, BS; Jennifer Robinson, PharmD Spokane,
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationCOMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE
CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You
More informationMedication burden in CKD-5D: impact of dialysis modality and setting
Clin Kidney J (2014) 7: 557 561 doi: 10.1093/ckj/sfu091 Advance Access publication 11 September 2014 Clinical Research Medication burden in CKD-5D: impact of dialysis modality and setting Kathrine Parker,
More informationUNDERSTANDING PROBLEMS OF TREATMENT ADHERENCE AS A CAUSE OF GRAFT LOSS
UNDERSTANDING PROBLEMS OF TREATMENT ADHERENCE AS A CAUSE OF GRAFT LOSS JOHN WEINMAN King s College London BTS ANNUAL CONGRESS, Brighton UK, 14 th March 2018 OVERVIEW OF THE TALK THE ADHERENCE PROBLEM AND
More information3/6/2017. Grassroots Strategies for Improving Adherence. Learning Objectives
Grassroots Strategies for Improving Adherence Amy Knight, PhD Director of Rehabilitation Psychology Department of Physical Medicine & Rehabilitation University of Alabama Birmingham Nothing to Disclose
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationTo Take or Not To Take?
To Take or Not To Take? Assessment Question How do the terms adherence & compliance differ? 1. The terms are synonymous 2.Adherence assumes collaboration between patient & provider while compliance suggests
More informationDisclosure. Learning Objectives 6/4/2014. Medication Adherence: Challenges and Opportunities
Medication Adherence: Challenges and Opportunities Jessica W. Skelley, Pharm D., BCACP Assistant Professor of Pharmacy Practice McWhorter School of Pharmacy, Samford University jmwhalen@samford.edu Disclosure
More informationAcceptance onto Dialysis Guidelines
Guidelines John Kelly (Kogarah, New South Wales) Melissa Stanley (Melbourne, Victoria) David Harris (Westmead, New South Wales) Date written: December 2004 Final submission: June 2005 Predialysis education
More informationclinical trial see commentary on page 471 A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
clinical trial http://www.kidney-international.org & 214 International Society of Nephrology OPEN see commentary on page 471 A phase III study of the efficacy and safety of a novel iron-based phosphate
More informationPrevalence of malnutrition in dialysis
ESPEN Congress Cannes 2003 Organised by the Israel Society for Clinical Nutrition Education and Clinical Practice Programme Session: Nutrition and the Kidney Malnutrition and Haemodialysis Doctor Noël
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationChronic Kidney Disease Mineral Bone Disease
NHS Logo here Chronic Kidney Disease Mineral Bone Disease (CKD-MBD) Patient Information Health & care information you can trust The Information Standard Certified Member Working together for better patient
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationLiterature Scan: Phosphate Binders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information21th Budapest Nephrology School Ágnes Haris, Kálmán Polner
21th Budapest Nephrology School Ágnes Haris, Kálmán Polner 53 years old female, -worked as computer scientist, -lived with her husband and 2 children, -in excellent financial situation. Diagnosed with
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationUnderstanding Your Medications
PD Education Booklet 8 Understanding Your Medications What you will learn: Why your medications are important Medications your kidney doctor may prescribe, and what they do Medications that may be added
More informationADHERENCE TO TREATMENT
ADHERENCE TO TREATMENT Understanding and supporting patients John Weinman & Zoe Moon King s College London OVERVIEW OF TALK - The Adherence problem and its effects - Adherence issues in cancer treatment
More informationImproving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help
Improving Adherence to Chronic Medications: The Physicians Role and How 340b Can Help William Shrank MD MSHS Division of Pharmacoepidemiology & Pharmacoeconomics Harvard Medical School wshrank@partners.org
More informationAdherence in multiple sclerosis: Neurologist s view
Adherence in multiple sclerosis: Neurologist s view Jaume Sastre-Garriga Unitat de Neuroimmunologia Clínica Centre d Esclerosi Múltiple de Catalunya CEMCat Hospital Universitari Vall d Hebron, Barcelona
More informationΚώστας Τσιούφης Iπποκράτειο Γ.Ν.Α
Χρόνιες παθήσεις, παράλληλη φαρμακευτική αγωγή και συμμόρφωση στη θεραπεία σε ασθενείς με συννοσηρότητα Ο ρόλος της πολυφαρμακίας και των πολλαπλών θεραπειών. H συμμόρφωση στη θεραπεία του ασθενή με συννοσηρότητες.
More informationMEDICATION ADHERENCE: WE DIDN T ASK & THEY DIDN T TELL
MEDICATION ADHERENCE: WE DIDN T ASK & THEY DIDN T TELL JENNIFER BUSSELL MD FACP INSTITUTE FOR HEALTHCARE IMPROVEMENT 15 TH ANNUAL INTERNATIONAL SUMMIT ON IMPROVING PATIENT CARE IN THE OFFICE PRACTICE AND
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More information7/22/2018. Team approach directed by the Department of Pharmacy for management of anemia and bone mineral disorder in chronic dialysis patients
Team approach directed by the Department of Pharmacy for manment of anemia and bone mineral disorder in chronic dialysis patients Disclosure Statement The authors of this presentation have research support
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationChapter six Outcomes: hospitalization & mortality. There is an element of death in life, and I am astonished
INTRODUCTION 1 OVERALL HOSPITALIZATION & MORTALITY 1 hospital admissions & days, by primary diagnosis & patient vintage five-year survival mortality rates, by patient vintage expected remaining lifetimes
More informationAdherence with Oral Bisphosphonate Therapy for Osteoporosis Among Patients in Canadian Clinical Practice. Not for Sale or Commercial Distribution
Adherence with Oral Bisphosphonate Therapy for Osteoporosis Among Patients in Canadian Clinical Practice Nader Habib, MD Heather McDonald-Blumer, MD Michele Moss, MBChB, MCFP Angèle Turcotte, MD Copyright
More informationCARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017
CARE FOR CHRONIC RENAL PATIENTS ROLE OF MULTIDISCIPLINARY APPROACH ÁGNES HARIS MD PHD, ST. MARGIT HOSPITAL, BUDAPEST BUDAPEST NEPHROLOGY SCHOOL, 2017 RENEGOTIATING LIFE WITH CHRONIC KIDNEY DISEASE CONSTANTINI
More informationIMPLEMENTATION OF THE CKD-MBD PRACTICE. Goce Spasovski, R. Macedonia
IMPLEMENTATION OF THE CKD-MBD GUIDELINES Introduction INTO CLINICAL to Renagel PRACTICE Goce Spasovski, R. Macedonia Antalya, Turkey, September 16 2012 Session Objectives Guidelines needs and controversy
More informationAPD and its new frontier. Roberto Pecoits-Filho, MD, PhD, FACP, FASN
APD and its new frontier Roberto Pecoits-Filho, MD, PhD, FACP, FASN STARCH Study Phase IV Randomised (1:1) Parallel groups Multi-centre Nephrol Dial Transpl 2015 Nov;30(11):1905-11. Non-diabetic APD
More informationBONE AND MINERAL METABOLISM in the PD PATIENT
BONE AND MINERAL METABOLISM in the PD PATIENT John Burkart, MD Professor of Medicine/Nephrology Wake Forest University Baptist Medical Center Chief Medical Officer Health Systems Management Maria V. DeVita,
More informationDoes Hemodialysis or Peritoneal Dialysis Provide a Better Quality of Life for Those with Chronic Kidney Disease? University of New Hampshire
Running head: QUALITY OF LIFE AMONG CKD PATIENTS Does Hemodialysis or Peritoneal Dialysis Provide a Better Quality of Life for Those with Chronic Kidney Disease? University of New Hampshire QUALITY OF
More information4Q and Full Year 2017 Financial Results Call February 7, 2018
4Q and Full Year 2017 Financial Results Call February 7, 2018 Agenda Topic Welcome Opening Remarks 4Q 2017 Results Commercial Progress Question & Answer Speakers Amy Sullivan, SVP, Corporate Affairs Greg
More informationNon-Compliance to Diet and Fluid Restrictions in Haemodialysis Patients
Non-Compliance to Diet and Fluid Restrictions in Haemodialysis Patients Abstract Pages with reference to book, From 293 To 295 Nilofer Safdar, Humera Baakza, Haren Kumar, S. A. J. Naqvi ( The Kidney Centre,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationYing-Ping Sun, Wen-Jun Yang, Su-Hua Li, Yuan-yuan Han, and Jian Liu
Hindawi BioMed Research International Volume 2017, Article ID 2516934, 5 pages https://doi.org/10.1155/2017/2516934 Research Article Clinical Epidemiology of Mineral Bone Disorder Markers in Prevalent
More informationAdherence to health behaviour advice in heart failure
Adherence to health behaviour advice in heart failure Prof. Nana Pogosova National Research Center for Preventive Medicine Moscow, Russian Federation Heart Failure (HF) As the final point for many cardiac
More informationEffect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
Research Article Effect of lanthanum and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease P. Thomas Scaria, Reneega Gangadhar 1, Ramdas Pisharody 2 ABSTRACT Departments
More informationPROTECTING HEART, VESSELS, AND BONE: NEW WAYS TO CONTROL PHOSPHORUS
PROTECTING HEART, VESSELS, AND BONE: NEW WAYS TO CONTROL PHOSPHORUS This symposium took place on 22 th May 2016 as part of the European Renal Association - European Dialysis and Transplant Association
More informationWhat Are the Targets in CKD-MBD?
Knowledge Exchange 2016 Paris, France, September 30, 2016 Date of preparation: Nov 2016 Item job code: INTSP/C-ANPROM/FOS/16/0025 Cristina Ortiz Jorge B Cannata-Andía Bone and Mineral Research Unit Hospital
More informationLesson 10: Self-Administration of Medication
Lesson 10: Self-Administration of Medication Transcript Title Slide (no narration) Welcome Hello. My name is Barbara Breen, Training Coordinator for the Department of Public Welfare Medication Administration
More informationOutcomes of dialysis in the elderly. DNT March 2011 Dr Céline Foote
Outcomes of dialysis in the elderly DNT March 2011 Dr Céline Foote Increasing number of elderly patients on renal replacement therapy 500 500 Patients per million 400 300 200 100 400 300 200 100 TOTAL
More informationPalliative and End of Life Care in End Stage Renal Disease
Palliative and End of Life Care in End Stage Renal Disease Palliative and End of Life Care Priority for Action Regional Consensus Workshop 30.06.2010 Neal Morgan Consultant Nephrologist SHSCT Outline Introduction
More informationHYPERKALEMIA: SURVEY OF AWARENESS AND EXPERIENCE AMONG ADULTS WITH CKD
HYPERKALEMIA: SURVEY OF AWARENESS AND EXPERIENCE AMONG ADULTS WITH CKD A Report of Findings March 6, 2017 TABLE OF CONTENTS Section Page READING OPTIONS: 5-in-1 Drill-down Report... iii ACKNOWLEDGEMENTS...
More informationParsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1
Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationBurden of end-stage renal disease
Summary of Indigenous health: End-stage renal disease Neil Thomson and Sasha Stumpers Australian Indigenous HealthInfoNet, Edith Cowan University www.healthinfonet.ecu.edu.au This summary of end-stage
More informationCommission of Dietetic Registration Board Certified Specialist in Renal Nutrition Certification Examination Content Outline
I. Nutrition Assessment and Re-assessment (36%) A. Food/Nutrition-Related History 1. Evaluate current nutrition intake, losses, and nutrient adequacy. 2. Assess nutritional needs related to ethnic and
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationGetting Hypertension Under Control
Getting Hypertension Under Control Learning Objectives EXPLAIN the factors involved in patient medication non-adherence. OUTLINE the results of studies focusing on medication adherence issues in patients
More informationChapter Five Clinical indicators & preventive health
Chapter Five Clinical indicators & preventive health The painter who draws merely by practice and by eye, without any reason, is like a mirror which copies every thing placed in front of it without being
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationHIV PREVENTION WITH PRE-EXPOSURE PROPHYLAXIS: A PRIMER FOR PHARMACISTS. Speaker: Susan MK Lee, PharmD, BCPS, CDE
Clinical Education Initiative Support@ceitraining.org HIV PREVENTION WITH PRE-EXPOSURE PROPHYLAXIS: A PRIMER FOR PHARMACISTS Speaker: Susan MK Lee, PharmD, BCPS, CDE 12/13/2016 HIV Prevention with Pre-Exposure
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationHypertension and the Challenge of Adherence. Geneva Clark Briggs, Pharm.D., BCPS
Hypertension and the Challenge of Adherence Geneva Clark Briggs, Pharm.D., BCPS Outline Brief overview of HTN and pharmacologic therapies Role of pharmacists in collaboration with patients and physicians
More informationLeverage Healthcare Technology Applications to Improve Primary Nonadherence.
Leverage Healthcare Technology Applications to Improve Primary Nonadherence. Page 2 Medication adherence starts with assessing a patient s opportunity for having positive outcomes on a specific therapy.
More informationDrug drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
J Nephrol (2014) 27:659 666 DOI 10.1007/s40620-014-0080-1 ORIGINAL ARTICLE Drug drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationMs. S, age 53, has bipolar disorder,
How you can simplify your patient s medication regimen to enhance adherence Colleen P. Hall, PharmD, BCPP Vicki L. Ellingrod, PharmD, FCCP Department Editor is produced in partnership with the College
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More information